ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

radiprodil

Also written as “Radiprodil”, “RGH-896” and “Radiprodil with Carbamazepine”.

Its studies are mostly in Tuberous Sclerosis · Neurodevelopmental Disorders · Spasms, Infantile · Pain, led by 3 companies.

Drug pageRadiprodil: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 31, 202510 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GRIN Therapeuticsits history only75 open or runningphase 3since Oct 31, 2025Feb 22, 2023Nov 2026phase 1 · NCT05818943
UCB20 open or runningphase 2since Jul 8, 2016Jan 4, 2016none ahead
AbbVieits history only10 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead

Also a collaborator on its studies: Angelini Pharma, Avance Clinical Pty, PRA Health Sciences and Gedeon Richter.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of UCB only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 4, 2016First study: phase 1 study in Healthy VolunteersFirst studyNCT02647697 · 10 enrolled · Netherlands
  2. Jul 8, 2016Phase 2 study in Spasms, InfantileNCT02829827 · 3 enrolled · France

TargetBeta

“Glutamate NMDA receptor; GRIN1/GRIN2B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsketamineruleJohnson & Johnsonphase 451
MemantineruleAbbViephase 429

Studies

All 2 UCB leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02829827Spasms, Infantile · France2TerminatedOct 2, 20183
NCT02647697Healthy Volunteers · Netherlands1CompletedFeb 201610

How it is read

Names in the registry

  • “Radiprodil”, 6 entries
  • “RGH-896”, 3 entries
  • “Radiprodil with Carbamazepine”, 1 entry
  • “Radiprodil with Itraconazole”, 1 entry
  • “Radiprodil + co-administered drugs”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.